Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

Martin van den Bent*, Hui K. Gan, Andrew B. Lassman, Priya Kumthekar, Ryan Merrell, Nicholas Butowski, Zarnie Lwin, Tom Mikkelsen, Louis B. Nabors, Kyriakos P. Papadopoulos, Marta Penas-Prado, John Simes, Helen Wheeler, Tobias Walbert, Andrew M. Scott, Erica Gomez, Ho Jin Lee, Lisa Roberts-Rapp, Hao Xiong, Earle BainPeter J. Ansell, Kyle D. Holen, David Maag, David A. Reardon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

108 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science